TKIs targeting EGFR are the primary treatment for NSCLC harboring activating mutations in the EGFR TK domain; unfortunately, resistance to EGFR-TKIs is unavoidable, and most of the patients experience a rapid cancer relapse [16,17,18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.